{"nctId":"NCT02669758","briefTitle":"A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia","startDateStruct":{"date":"2016-01-20","type":"ACTUAL"},"conditions":["Schizophrenia"],"count":281,"armGroups":[{"label":"ALKS 3831","type":"EXPERIMENTAL","interventionNames":["Drug: ALKS 3831"]}],"interventions":[{"name":"ALKS 3831","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject has completed the 4-week treatment period (all visits up to and including end of treatment visit) in the antecedent study ALK3831-A305 within 7 days.\n* Agrees to use an acceptable method of contraception for the duration of the study.\n* Additional criteria may apply.\n\nExclusion Criteria:\n\n* Subject is currently taking medications that are contraindicated with olanzapine use.\n* Subject has a positive test for drugs of abuse at study entry.\n* Subject is pregnant, planning to become pregnant, or breastfeeding during the study.\n* Additional criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events (AEs)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"136","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":277},"commonTop":["Weight increased","Somnolence","Headache","Nasopharyngitis","Extra dose administered"]}}}